poster

Successful Buprenorphine/Naloxone High-dose Induction in Pregnancy

Medication for opioid use disorder (OUD) with methadone or buprenorphine/naloxone is recommended for pregnant women with OUD. Traditional buprenorphine/naloxone induction requires patient...

10/26/2023

SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany

This real-world study examined initiation strategies and subsequent outcomes for solriamfetol (Sunosi®), a wake-promoting agent used to treat excessive daytime sleepiness (EDS) in obstruc...

10/26/2023

Sleep Disturbances Are Highly Predictive of Major Depressive Disorder Recurrence

This longitudinal study evaluated the impact of sleep disturbances, including hypersomnolence, on the progress of major depressive disorder (MDD) over a 3-year period. Participant charact...

10/26/2023

SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of TV-44749 for Subcutaneous Use (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Intramuscular long-acting injectable olanzapine is approved for treatment of schizophrenia in adults but has an associated risk for post-injection delirium/sedation syndrome. The Subcutan...

10/26/2023

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

This post-hoc analysis of two phase 3 studies demonstrates that solriamfetol, an approved treatment for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea, ...

10/26/2023

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP)

Solriamfetol is a dopamine-norepinephrine reuptake inhibitor (DNRI) that improves wakefulness in adults with EDS and OSA. Beyond inhibiting DAT/NET, solriamfetol demonstrated agonist acti...

10/26/2023

Safety and Efficacy of Low-Sodium Oxybate in Participants With Narcolepsy With and Without Psychiatric Comorbidities: Subgroup Analysis of a Phase 3 Clinical Trial

This study assessed safety and efficacy of low-sodium oxybate (LXB) in participants with narcolepsy both with and without comorbid psychiatric disorders in a phase 3 clinical study. Safet...

10/26/2023

Safety and Tolerability of Zuranolone 50 mg in Patients with Major Depressive Disorder: Results from the Phase 3 WATERFALL and CORAL Studies

Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...

10/26/2023

Screening for Obsessive Compulsive Disorder among college students using the Obsessive Compulsive Inventory-4

This study aimed to assess the efficacy of the Obsessive Compulsive Inventory questionnaire (OCI-4), a four-item OCD screening tool used to detect OCD, in a cohort of college students. Th...

10/26/2023

Shaping Psychiatric Pharmacy Through Stewardship and Standardized Outcomes

The American Association of Psychiatric Pharmacists (AAPP) has sought to operationalize the concept of psychotropic stewardship through formalizing a consensus-based set of outcomes and m...

10/26/2023

Tracks

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products